Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 May 2024
The study discovers that the survival rate is similar to that of the VIALE-A trial's younger patients.
Read Full NewsQurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes
1.
How 7,000 steps a day could help reduce your risk of cancer
2.
The biology of cancer as well as potential treatment options are examined by experts.
3.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
4.
New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.
5.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
1.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
2.
Contemporary Frameworks in Oncology Across Clinical Settings
3.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
4.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
5.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Prevention of Heparin-Induced Thrombocytopenia Complications Through Platelet Activation Signature Monitoring
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
5.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge